查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1965990

流感药物市场－全球产业规模、份额、趋势、机会、预测：按药物类型、分销管道、地区和竞争格局划分，2021-2031年

Influenza Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球流感治疗市场预计将从 2025 年的 9.7113 亿美元成长到 2031 年的 14.1622 亿美元，复合年增长率为 6.49%。

该领域涵盖抗病毒疗法和预防性疫苗，旨在降低季节性流感和流行性流感病毒株的严重程度。推动该市场成长要素是全球呼吸道病毒感染疾病的增加以及全球人口老化导致的易感性上升。此外，各国政府为应对疫情而製定的严格规定以及对医疗物资的策略性储备，也为市场发展的可持续发展奠定了基础。

市场概览
预测期 2027-2031
市场规模：2025年 9.7113亿美元
市场规模：2031年 1,416,220,000 美元
复合年增长率：2026-2031年 6.49%
成长最快的细分市场 奥司他韦
最大的市场 北美洲

病毒抗原漂移速度极快，这是市场扩张的一大障碍，随着时间的推移，这可能会降低现有治疗方法和预防措施的有效性。儘管面临这项持续挑战，製药业仍致力于创新，并大力投资对抗病毒抗药性。据国际药品製造商协会联合会（IFPMA）称，到2025年，将有超过30种流感疫苗候选产品进入临床试验阶段，这表明该领域正致力于应对不断演变的生物威胁。

市场驱动因素

政府的战略储备和应对疫情的倡议是市场的主要驱动因素，各国政府正积极确保疫苗供应，以应对通用感染疾病的威胁。公共卫生机构优先资助新技术，以确保在疫情爆发时能够快速生产疫苗，从而降低製药公司的商业风险。例如，2024年7月，美国卫生与公共服务部宣布，生物医学高级研究与发展局已向Modena Pharmaceuticals公司拨款约1.76亿美元，用于支持其开发基于mRNA技术的流感大流行疫苗。这凸显了疫苗研发策略朝向能够快速应对新病毒株的灵活平台转变。

此外，季节性流感在全球范围内的发病率不断上升，以及禽流感病毒株带来的迫在眉睫的威胁，正在推动市场成长，因为这些因素都要求建立健全的治疗和预防药物供应链。高感染率给医疗保健系统带来了沉重的负担，并确保了不同人群对有效干预措施的持续需求。根据美国疾病管制与预防中心 (CDC) 2024 年 10 月的报告，2023-2024 年流感季期间，美国估计有 3,500 万人感染流感。为了因应类似的跨国威胁，国际采购机制也不断扩大。例如，2024 年，CCS Seqirus 与欧盟委员会签订了一份合同，供应多达 66.5 万剂动物性流感疫苗，以降低潜在的疫情风险。

市场挑战

抗原漂移的快速发展是全球流感治疗市场持续成长的主要障碍。这种持续的基因演化机制会改变病毒的表面蛋白，使其能够频繁地逃避先前感染或疫苗接种所建立的免疫力。因此，现有抗病毒药物和疫苗的临床效用迅速下降，可能导致治疗效果降低和公众信心下降。这种不稳定性迫使製造商陷入持续且资源密集的产品重新设计和临床试验循环，造成巨大的财务风险和业务不确定性，阻碍市场长期扩张。

这项挑战的严峻性体现在这尚未解决的健康威胁所造成的巨大经济影响。由于即使存在治疗方法，病毒也无法被彻底清除，因此持续高成本的疫情爆发给医疗系统带来了沉重负担。根据国际药品製造商协会联合会（IFPMA）预测，到2024年，欧盟成年人季节性流感造成的经济负担预计将高达每年140亿欧元。如此巨大的经济负担凸显了市场在克服病毒不断进化的抗药性方面所面临的困境，因为即使是已有的治疗方法也难以在病毒不断变异的靶点面前保持疗效。

市场趋势

新冠病毒和流感联合疫苗的开发平臺不断扩展，正迅速改变市场竞争格局，提供简化的免疫接种方案，有效解决疫苗接种疲劳和物流效率低下等问题。製造商正专注于研发这些双抗原候选疫苗，以提高患者依从性并简化年度免疫接种程序，尤其适用于需要抵抗多种呼吸道病原体的老年族群。这种整合方案兼顾了疫苗的有效性和便利性，从而提升了市场价值。例如，2024年6月，Moderna公司报告称，其在研的mRNA-1083疫苗对三种流感病毒株和SARS-CoV-2病毒均产生了统计学意义上的显着更高的免疫反应。在65岁及以上成年人中，该疫苗对H1N1病毒株的几何平均免疫反应率达1.155，高于已已通过核准的对照疫苗。

无针鼻腔给药系统的出现标誌着医疗模式向去中心化模式的重大转变，减少了对临床基础设施的依赖，并克服了侵入性给药的障碍。透过证明自我给药方案的有效性，该行业正在扩大家庭和药房的网路基地台，从而提高犹豫接种人群和儿童的疫苗接种率。据Astra Zeneca称，其用于自我给药的FluMist已于2024年9月核准FDA批准，可用性研究表明，18至49岁的目标用户100%能够完成全剂量给药，证实了这种给药方式具有广泛应用的潜力。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球流感药物市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 药物类型（Ribavirin、奥司他韦、瑞乐沙、帕拉米韦、流感疫苗）
    • 分销通路（医院药局、零售药局、线上通路）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美流感药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲流感药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区流感药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲流感药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美流感药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球流感药物市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • FACCUSA Laboratories Inc
  • Lonza Group Ltd
  • Bristol-Myers Squibb Co
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novo Nordisk A/S
  • Sanofi SA
  • Bayer AG
  • Banting Medical Inc
  • Cipla Limited

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 18996

The Global Influenza Drugs Market is projected to expand from USD 971.13 Million in 2025 to USD 1416.22 Million by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 6.49%. This sector comprises antiviral therapeutics and prophylactic vaccines aimed at mitigating the severity of both seasonal and pandemic influenza strains. The market is primarily driven by the rising global prevalence of respiratory viral infections and the increased susceptibility of an aging global population. Furthermore, stringent government mandates regarding pandemic preparedness, along with the strategic stockpiling of medical countermeasures, provide a consistent foundation for continued market development.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 971.13 Million
Market Size 2031USD 1416.22 Million
CAGR 2026-20316.49%
Fastest Growing SegmentOseltamivir
Largest MarketNorth America

A major obstacle to broader market expansion is the rapid antigenic drift of the virus, which can render existing treatments and preventive measures less effective over time. Despite this persistent challenge, the pharmaceutical industry remains committed to innovation and investing heavily to combat viral resistance. According to the International Federation of Pharmaceutical Manufacturers and Associations, there are over 30 influenza vaccine candidates in active clinical trials in 2025, underscoring the sector's dedication to addressing these evolving biological threats.

Market Driver

Strategic government stockpiling and pandemic preparedness initiatives serve as a primary catalyst for the market, with authorities actively securing vaccine supplies to counter zoonotic threats. Public health agencies are prioritizing funding for new technologies to guarantee rapid manufacturing capabilities during outbreaks, thereby reducing commercial risks for pharmaceutical developers. For example, the U.S. Department of Health and Human Services announced in July 2024 that the Biomedical Advanced Research and Development Authority awarded Moderna approximately USD 176 million to support the development of an mRNA-based pandemic influenza vaccine, highlighting a strategic shift toward flexible platforms capable of quickly addressing novel viral strains.

Additionally, the increasing global incidence of seasonal influenza and the looming threat of avian strains drive market growth by necessitating robust supply chains for therapeutics and preventatives. High transmission rates result in significant medical burdens, ensuring consistent demand for effective interventions across various demographics. According to the Centers for Disease Control and Prevention's October 2024 report, there were an estimated 35 million influenza illnesses in the United States during the 2023-2024 season. To address similar cross-border threats, procurement mechanisms are expanding internationally; for instance, CSL Seqirus secured an agreement in 2024 to supply the European Commission with up to 665,000 doses of zoonotic influenza vaccine to mitigate potential outbreak risks.

Market Challenge

Rapid antigenic drift represents a primary barrier to the sustained growth of the Global Influenza Drugs Market. This mechanism of constant genetic evolution modifies the virus's surface proteins, frequently allowing it to evade immunity established by prior exposure or vaccination. Consequently, the clinical utility of existing antiviral drugs and vaccines can diminish swiftly, leading to reduced therapeutic effectiveness and lower public confidence. This volatility forces manufacturers into a continuous, resource-intensive cycle of product reformulation and clinical testing, creating significant financial risks and operational uncertainties that hinder long-term market expansion.

The severity of this challenge is illustrated by the substantial economic impact of this unresolved health threat. The inability to permanently neutralize the virus results in persistent, high-cost outbreaks that burden healthcare systems, even when therapeutics are available. According to the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the economic burden of seasonal influenza among adults in the European Union was reported to reach up to €14 billion annually in 2024. This heavy financial toll underscores the difficulty the market faces in overcoming the virus's evolutionary resilience, as even established treatments struggle to maintain their value against constantly shifting viral targets.

Market Trends

The pipeline expansion of combined COVID-19 and influenza vaccines is rapidly reshaping the competitive landscape by offering streamlined immunization solutions that address vaccine fatigue and logistical inefficiencies. Manufacturers are focusing on these dual-antigen candidates to improve patient compliance and simplify annual vaccination schedules, especially for older adults who need protection against multiple respiratory pathogens. This integration drives market value by combining efficacy with convenience; for instance, Moderna reported in June 2024 that its investigational mRNA-1083 vaccine elicited statistically significantly higher immune responses against three influenza strains and SARS-CoV-2, achieving a Geometric Mean Ratio of 1.155 for the H1N1 strain in adults aged 65 and older compared to licensed comparators.

The emergence of needle-free and intranasal drug delivery systems marks a major shift toward decentralized care models, reducing reliance on clinical infrastructure and overcoming barriers associated with invasive administration. By validating self-administered options, the industry is extending access points to homes and pharmacies, potentially increasing coverage rates among hesitant demographics and pediatric populations. According to AstraZeneca, in September 2024, the FDA approval of FluMist for self-administration was supported by usability studies demonstrating that 100% of intended users aged 18 to 49 could successfully administer a full dose, confirming the feasibility of this delivery method for widespread public use.

Key Market Players

  • FACCUSA Laboratories Inc
  • Lonza Group Ltd
  • Bristol-Myers Squibb Co
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novo Nordisk A/S
  • Sanofi S.A
  • Bayer AG
  • Banting Medical Inc
  • Cipla Limited

Report Scope

In this report, the Global Influenza Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Influenza Drugs Market, By Drug Type

  • Ribavirin
  • Oseltamivir
  • Relenza
  • Peramivir
  • Influenza Vaccines

Influenza Drugs Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channel

Influenza Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Influenza Drugs Market.

Available Customizations:

Global Influenza Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Influenza Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Ribavirin, Oseltamivir, Relenza, Peramivir, Influenza Vaccines)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Influenza Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Influenza Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Influenza Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Influenza Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Distribution Channel

7. Europe Influenza Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Influenza Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Influenza Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Influenza Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Influenza Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Influenza Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Influenza Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Influenza Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Influenza Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Influenza Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Influenza Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Influenza Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Influenza Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Influenza Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Influenza Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Influenza Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Distribution Channel

10. South America Influenza Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Influenza Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Influenza Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Influenza Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Influenza Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. FACCUSA Laboratories Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Lonza Group Ltd
  • 15.3. Bristol-Myers Squibb Co
  • 15.4. Pfizer Inc.
  • 15.5. GlaxoSmithKline plc
  • 15.6. Novo Nordisk A/S
  • 15.7. Sanofi S.A
  • 15.8. Bayer AG
  • 15.9. Banting Medical Inc
  • 15.10. Cipla Limited

16. Strategic Recommendations

17. About Us & Disclaimer